Plasma that can be stored on a shelf at room temperature and mixed for transfusion in minutes is now licensed for use in the United States for the first time.
The Food and Drug Administration announced on July 29 that it licensed Ezplaz Freeze Dried Plasma, and the agency was specific about who it is for. Ezplaz is cleared for transfusion in adult patients who need plasma and for whom other plasma products are not available. That availability condition is part of the license, not a footnote to it.
The practical target is the setting where conventional plasma cannot realistically be kept: a military field hospital, a helicopter, a rural clinic hours from a blood bank, a disaster zone where power and freezers have failed.
What the FDA Licensed and What It Is For
Conventional plasma must be stored frozen and thawed before it can be used, a process that takes time a hemorrhaging patient may not have and equipment an austere setting may not have.
Ezplaz is freeze-dried, or lyophilized, and made from a single unit of fresh frozen plasma collected at FDA-licensed blood establishments. According to the FDA news release, it can be stored at room temperature, remains stable after exposure to temperature fluctuations, and is rapidly reconstituted. It is packaged in a plastic bag rather than a glass bottle, which reduces the risk of breakage during transport.
Each kit is self-contained: one unit of freeze-dried plasma in a foil pouch, a 250 mL bag of sterile water for injection, a sterile fluid transfer set, and a sterile blood transfusion set. Nothing else has to be on hand.
The product comes in Group AB and in Group A with low titer anti-B. Those types were chosen deliberately so the product can be given in an emergency before a patient's blood type has been determined.
The license names three situations covered by the indication: bleeding patients, patients needing massive transfusion, and certain patients on warfarin who are bleeding. All of them are adults, and all of them are conditioned on other plasma products being unavailable.
Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research, said in the announcement that "Patients experiencing life-threatening bleeding in combat zones, disasters, rural settings" may now have faster access to plasma when frozen plasma is not an option.
The FDA granted the biologics license to Vascular Solutions, LLC, a subsidiary of Teleflex.
Why This Is Not a Fix for the Current Blood Shortage
This licensure arrives in the same week the American Red Cross declared only its second national blood supply crisis and began limiting distributions of type O blood to hospitals. The two stories are related, but they are not the same story, and conflating them would mislead readers.
The current shortage is primarily a red blood cell problem, and specifically a type O red cell problem. Plasma is a different blood component with a different function: it carries clotting factors and is transfused to control bleeding, not to carry oxygen. A freeze-dried plasma product does not add a single unit of red cells to the supply.
Ezplaz also does not create plasma out of nothing. It is manufactured from donated fresh frozen plasma, so it still depends entirely on volunteer donors. What it changes is where plasma can be stored and how quickly it can be used, not how much of it exists.
And the indication itself limits substitution. Ezplaz is licensed for use when other plasma products are not available, which means it is not intended to replace conventional plasma in a hospital that has a working freezer.
Where it may matter over time is waste and reach. Thawed plasma has a short usable window, and units that expire unused are units lost. A shelf-stable product that travels in a plastic bag could extend plasma to places that have never been able to stock it.
How This Product Reached Approval
Freeze dried plasma is not a new idea. It was used by American forces during the Second World War and then largely abandoned in the United States over hepatitis transmission concerns, while several other countries continued developing their own versions. American military clinicians have spent years relying on allied supplies or investigational protocols in the field.
Freeze-dried plasma was among the first products identified under Public Law 115-92, enacted in December 2017, which authorized a collaboration between the Defense Department and the FDA to speed development and review of products for serious or life-threatening conditions facing U.S. military personnel. The FDA then issued guidance in 2019 to help manufacturers develop dried plasma for transfusion.
Anne Eder, director of the FDA's Office of Blood Research and Review, framed the decision as evidence that the agency can expand "treatment options and novel blood components while maintaining FDA's standards" for safety, purity, and potency.
What Is Known About Safety and What Is Not
The FDA said it found that the benefits of Ezplaz transfusion outweigh the risks for the uses approved under the license, and that the product's safety profile is consistent with other plasma products used for transfusion. That is a meaningful statement, and it is also a bounded one: consistent with other plasma means it carries the risks plasma already carries.
Plasma transfusion risks include allergic and hypersensitivity reactions, transfusion-related acute lung injury, transfusion-associated circulatory overload, and febrile reactions. The FDA directed clinicians to review the full prescribing information before use.
Several things are not established. The license covers adults only, so there is no approved pediatric use. The FDA release does not state when Ezplaz will reach hospitals, how it will be priced, or how it will be distributed. Nor does it describe how many patients were studied or report head to head outcomes against frozen plasma, so readers should not assume equivalence in routine hospital care.
There is nothing here for a patient to act on individually. No one can request this product, and its use is a clinical decision made in emergencies, usually when the patient cannot participate.
What Happens Next
The immediate questions are logistical: when Vascular Solutions begins distribution, which military units and civilian trauma systems adopt it first, and whether emergency medical services agencies pursue protocols for carrying it. Whether the manufacturer seeks a broader indication or pediatric data is also unresolved.
For readers, the useful action is the ordinary one. Plasma still comes from donors, and the national supply is under strain. Eligible donors can find a drive through RedCrossBlood.org or 1-800-RED CROSS. People with fever, active diarrheal illness, or a recent infection should wait and check eligibility before booking.
The bottom line: the FDA has licensed the first freeze-dried plasma in the United States, cleared for adults who need plasma when no other plasma product is available. The people most likely to benefit are trauma patients far from a hospital blood bank, including military personnel. There is no individual action for patients to take, and the most reasonable contribution is blood donation. The central uncertainty is when and where the product will actually be available.
Frequently Asked Questions
What did the FDA approve? Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product licensed in the United States, for transfusion in adults who need plasma and for whom other plasma products are not available.
How is it different from regular plasma? Conventional plasma must be stored frozen and thawed before use. Ezplaz is stored at room temperature, tolerates temperature swings, and is reconstituted quickly. It ships in a plastic bag rather than a glass bottle.
Does this solve the current blood shortage? No. The shortage is mainly a type O red blood cell problem. Plasma is a different component, and Ezplaz is made from donated plasma, so it still depends on volunteer donors.
Can children receive it? Not under this license. Ezplaz is approved for adults only.
Is it as safe as frozen plasma? The FDA said its safety profile is consistent with other plasma products used for transfusion, which means it carries the risks plasma already carries, including allergic reactions and lung or circulatory complications.
Can I ask my hospital for it? No. It is licensed for emergency situations where other plasma is unavailable, and its use is a clinical decision.
When will it be available? The FDA release did not give a distribution date or price. The license went to Vascular Solutions, LLC, a Teleflex subsidiary.
